Neuraxpharm establishes operations in the Republic of Ireland through the acquisition of Medinutrix

Neuraxpharm acquires Medinutrix Ltd to provide an immediate platform for the recently acquired market-leading epilepsy treatment Buccolam® in Ireland

Düsseldorf and Barcelona, December 14, 2020 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on disorders of the central nervous system (CNS), today announces the expansion of its operations in Northwestern Europe with the launch of Neuraxpharm Ireland, and the acquisition of Medinutrix Ltd (trading as Aribamed), a privately-owned specialty pharmaceutical distribution company.

With this acquisition, Neuraxpharm now has both the platform and the local expertise to launch new products in the Irish market for the first time, and will start to build its position as a CNS specialist in the Republic of Ireland. Neuraxpharm will leverage its CNS expertise to make available suitable products, out of its extensive portfolio, including the recently acquired market-leading Buccolam® for emergency treatment of epileptic children and adolescents.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH